Artificial tears are eye drops or ointments designed to lubricate the eyes and provide relief from dryness and discomfort. These products are commonly used to treat conditions such as dry eye syndrome, which can result from factors like aging, environmental conditions, prolonged screen time, or certain medical conditions.
Recall Updates In February 2023, the FDA issued a recall for EzriCare Artificial Tears and Delsam Pharma's Artificial Eye Ointment due to potential bacterial contamination. This incident highlighted the importance of manufacturing quality and safety in the artificial tears market.
Allergan (US) Launched Refresh® Bio, a new line of preservative-free and biocompatible artificial tears in July 2023, catering to users with sensitive eyes or preservative allergies.
Bausch + Lomb (US) Announced plans to expand its line of Systane® Complete artificial tears with new formulations addressing specific dry eye symptoms, offering targeted relief options for patients.
Johnson & Johnson (US) Received FDA approval for its Acuvue® Oasys with TearRelief Technology contact lenses in September 2023, which integrate a moisturizing agent within the lens for enhanced comfort and dryness relief.
Thea Laboratories (France) Collaborated with AI startup TearLab Corp. (US) to develop AI-powered diagnostic tools for personalized dry eye management, aiming to tailor treatment plans based on individual tear film analysis.
Artificial Tears Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)